NICE technology appraisal guidance TA875 recommends semaglutide for use within specialist weight management services, subject to specific eligibility criteria: a BMI of 35 kg/m or above, or a lower BMI threshold for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds, alongside at least one weight-related comorbidity, and as part of a specialist multidisciplinary programme
Also, dihexa can be delivered via parenteral routes of administration
Four structural limitations define how the evidence must be interpreted before any application to humans is considered
The active molecule is the same
According to the journal Obesity (Silver Spring), phentermine has been deemed safe and effective for weight loss, but adverse side effects are still possible [5]
A consultation with a healthcare provider can help determine if NAD therapy is appropriate for each person